Clinic
Port Charlotte Hma LLC
Port Charlotte Hma LLC was paid $6.42M by Medicaid between Jan 2018 and Dec 2024, across 166 billing codes. Its largest line is 99283, emergency room visit (moderate) — 23% of everything it billed.
33Billing provider infoPORT CHARLOTTE HMA LLC
PORT CHARLOTTE, FL 33952
PORT CHARLOTTE, FL 33952
33aNPI1053364703assigned 05/17/2006
33bProvider typeUrgent Care Clinic/Center
28Total paid$6.42M
24GClaims301,356
24DCodes billed166
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Urgent Care Clinic/Center providers in Florida
Rank by total paid#5 of 115
Median peer was paid$106K
This provider vs. median61×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official LALOR, PAULA controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 22,579 | $414K | |
| 2019 | 59,518 | $1.02M | |
| 2020 | 48,846 | $700K | |
| 2021 | 67,513 | $1.36M | |
| 2022 | 63,638 | $1.52M | |
| 2023 | 25,466 | $785K | |
| 2024incomplete | 13,796 | $634K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 23% | 18,610 | 16,540 | $1.45M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 14% | 12,463 | 10,504 | $884K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 8.1% | 6,036 | 5,480 | $522K |
| 36415 | Collection of venous blood by venipuncture | 4.4% | 16,525 | 11,840 | $282K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 4.1% | 1,367 | 1,193 | $262K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 4.0% | 1,677 | 1,408 | $255K |
| 70450 | Computed tomography, head or brain; without contrast material | 3.6% | 2,495 | 2,006 | $234K |
| 96361 | Intravenous infusion, hydration; each additional hour | 3.6% | 4,822 | 3,960 | $233K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 3.0% | 4,179 | 3,354 | $194K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | 2.9% | 2,711 | 2,487 | $185K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 2.6% | 2,737 | 2,217 | $167K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 2.0% | 2,751 | 2,342 | $126K |
154 more codes
| 80053 | Comprehensive metabolic panel | 1.8% | 11,772 | $112K |
| 80306 | 1.5% | 1,624 | $94K | |
| 86900 | 1.2% | 1,800 | $77K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 1.1% | 2,062 | $71K |
| 86901 | <1% | 2,339 | $64K | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 2,195 | $63K |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 1,644 | $59K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 2,185 | $58K |
| G0378 | Hospital observation service, per hour | <1% | 3,562 | $51K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 1,748 | $50K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 3,686 | $48K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 407 | $45K |
| 87430 | <1% | 6,163 | $41K | |
| 85610 | <1% | 4,898 | $39K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 4,521 | $37K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 220 | $33K |
| 85027 | <1% | 7,168 | $30K | |
| 87807 | <1% | 1,726 | $28K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 309 | $28K |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 2,405 | $23K |
| 93976 | <1% | 1,251 | $22K | |
| 85730 | <1% | 4,181 | $21K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 1,559 | $21K |
| 87400 | <1% | 3,057 | $20K | |
| 82962 | <1% | 2,650 | $20K | |
| 71045 | Radiologic examination, chest; single view | <1% | 6,777 | $20K |
| J2704 | Injection, propofol, 10 mg | <1% | 2,499 | $19K |
| 80047 | <1% | 1,815 | $18K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 1,897 | $17K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 551 | $17K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 4,264 | $16K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 11,553 | $15K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 6,615 | $14K |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 1,128 | $14K |
| 81003 | <1% | 5,899 | $14K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 5,140 | $13K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 1,509 | $13K |
| 81025 | <1% | 2,756 | $13K | |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 486 | $13K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 3,134 | $12K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 13,474 | $12K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 1,565 | $12K |
| 84702 | <1% | 1,480 | $11K | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 1,164 | $10K |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 564 | $10K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 258 | $10K |
| 73630 | <1% | 401 | $9K | |
| 73610 | <1% | 309 | $8K | |
| 81001 | <1% | 6,504 | $8K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 619 | $7K |
| 76801 | <1% | 605 | $7K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 4,430 | $7K |
| 96376 | <1% | 1,288 | $6K | |
| 83735 | <1% | 4,387 | $6K | |
| 84484 | <1% | 4,957 | $6K | |
| 73130 | <1% | 191 | $6K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 6,269 | $6K |
| 76830 | Ultrasound, transvaginal | <1% | 384 | $6K |
| 92587 | <1% | 213 | $6K | |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 34 | $5K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 302 | $5K |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 688 | $5K |
| C1769 | Guide wire | <1% | 346 | $5K |
| 74018 | <1% | 171 | $5K | |
| 92650 | <1% | 124 | $4K | |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 1,059 | $4K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 171 | $4K |
| 83690 | <1% | 3,072 | $3K | |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 15 | $3K |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 2,056 | $3K |
| 86850 | <1% | 1,611 | $3K | |
| 82550 | <1% | 2,082 | $3K | |
| 72131 | <1% | 58 | $2K | |
| 87077 | <1% | 1,476 | $2K | |
| 82553 | <1% | 1,953 | $2K | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 1,248 | $2K |
| 84703 | <1% | 1,222 | $2K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 45 | $2K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 3,477 | $2K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 221 | $2K |
| 87186 | <1% | 1,140 | $2K | |
| 73110 | <1% | 56 | $1K | |
| 87070 | <1% | 604 | $1K | |
| 83880 | <1% | 625 | $992.30 | |
| 87653 | <1% | 63 | $979.18 | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 5,999 | $971.30 |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 338 | $921.75 |
| 82077 | <1% | 105 | $838.57 | |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 14 | $770.28 |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 861 | $713.85 |
| 85380 | <1% | 650 | $648.17 | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 257 | $613.68 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 1,888 | $540.77 |
| 73562 | <1% | 77 | $512.14 | |
| 82150 | <1% | 1,302 | $491.36 | |
| 87040 | <1% | 817 | $489.65 | |
| 86141 | <1% | 26 | $479.44 | |
| 93970 | <1% | 27 | $470.80 | |
| 73564 | <1% | 25 | $420.57 | |
| 12011 | <1% | 12 | $366.92 | |
| 73030 | <1% | 71 | $313.65 | |
| 80076 | <1% | 1,140 | $292.17 | |
| 80061 | Lipid panel | <1% | 273 | $249.69 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 1,451 | $249.56 |
| 36416 | <1% | 53 | $189.20 | |
| C9290 | Injection, bupivacaine liposome, 1 mg | <1% | 12 | $142.25 |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 102 | $142.25 |
| 87205 | <1% | 94 | $129.11 | |
| 82247 | <1% | 117 | $125.68 | |
| 92651 | <1% | 340 | $115.44 | |
| 84439 | <1% | 12 | $112.79 | |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 420 | $110.80 |
| 85379 | <1% | 485 | $98.15 | |
| 82248 | <1% | 302 | $69.94 | |
| 92652 | <1% | 51 | $57.72 | |
| 73560 | <1% | 13 | $54.91 | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 164 | $50.05 |
| 92558 | <1% | 14 | $46.97 | |
| 87806 | <1% | 34 | $42.12 | |
| 86592 | <1% | 132 | $40.10 | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 46 | $30.79 |
| 29125 | <1% | 17 | $29.95 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 100 | $24.81 |
| 80074 | <1% | 14 | $23.89 | |
| 81000 | <1% | 268 | $22.87 | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 67 | $21.70 |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 45 | $5.38 |
| J2060 | Injection, lorazepam, 2 mg | <1% | 192 | $5.22 |
| 86762 | <1% | 31 | $3.05 | |
| 87340 | <1% | 73 | $2.69 | |
| 87147 | 0% | 52 | $0.00 | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | 0% | 114 | $0.00 |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | 0% | 21 | $0.00 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | 0% | 238 | $0.00 |
| 94760 | 0% | 601 | $0.00 | |
| 94761 | 0% | 105 | $0.00 | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 0% | 45 | $0.00 |
| 83605 | 0% | 257 | $0.00 | |
| 93971 | 0% | 14 | $0.00 | |
| 12001 | 0% | 13 | $0.00 | |
| J3490 | Unclassified drugs | 0% | 121 | $0.00 |
| 85651 | 0% | 19 | $0.00 | |
| J2550 | Injection, promethazine hcl, up to 50 mg | 0% | 35 | $0.00 |
| J3475 | Injection, magnesium sulfate, per 500 mg | 0% | 152 | $0.00 |
| J7510 | Prednisolone oral, per 5 mg | 0% | 123 | $0.00 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | 0% | 186 | $0.00 |
| 84112 | 0% | 28 | $0.00 | |
| 99152 | 0% | 65 | $0.00 | |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | 0% | 18 | $0.00 |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | 0% | 20 | $0.00 |
| 85007 | 0% | 15 | $0.00 | |
| 00731 | 0% | 12 | $0.00 | |
| 81002 | 0% | 42 | $0.00 | |
| 84100 | 0% | 20 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialLALOR, PAULA (DIRECTOR)
| Provider | Location | Paid |
|---|---|---|
| Northwest Hospital LLC | Tucson, AZ | $47.81M |
| Roswell Hospital Corporation | Roswell, NM | $41.27M |
| Wesley Health System LLC | Hattiesburg, MS | $37.82M |
| Metro Knoxville Hma LLC | Powell, TN | $28.70M |
| Bullhead City Hospital Corporation | Bullhead City, AZ | $28.54M |
| Iom Health System LP | Fort Wayne, IN | $27.50M |
| ST. Joseph Health System, LLC | Fort Wayne, IN | $25.43M |
| Laredo Texas Hospital Company LP | Laredo, TX | $19.46M |
| Oak Hill Hospital Corporation | Oak Hill, WV | $18.77M |
| Cocke County Hma, LLC | Newport, TN | $18.34M |
| Cleveland Tennessee Hospital Company LLC | Cleveland, TN | $16.31M |
| Jefferson County Hma LLC | Jefferson City, TN | $14.31M |
| Northwest Arkansas Hospitals, LLC | Springdale, AR | $11.46M |
| Petersburg Hospital Company LLC | Petersburg, VA | $11.20M |
| Campbell County Hma, LLC | Lafollette, TN | $10.07M |
| Warsaw Health System LLC | Warsaw, IN | $9.95M |
| Longview Medical Center LP | Longview, TX | $9.29M |
| Moberly Hospital Company LLC | Moberly, MO | $8.61M |
| Crestview Hospital Company, LLC | Crestview, FL | $8.15M |
| Kirksville Missouri Hospital Company, LLC | Kirksville, MO | $7.98M |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.